Article
Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 Dec 2001
Adan R A, Vink T
Abstract excerpt
The identification of the genetic defect underlying the obese phenotype of the viable yellow mouse, ectopic overexpression of the agouti protein which acts as antagonist at the melanocortin-4 receptor, together with the demonstration that the brain melanocortin system was one major downstream effector pathway of leptin signaling has put forward melanocortin receptors as drug targets for obesity. The lack of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.